Analytical Data
-
基因名
Complement factor I
- Application
-
别名
CF-I; C3b-INA; FI; IF; KAF; Factor I; Konglutinogen-Activating Factor; C3b-Inactivator; C3B/C4B inactivator
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q61129
-
表达区间
Arg358~Val603
-
分子量
31kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Complement factor I (CFI) is a key regulatory protein in the complement system, which plays a crucial role in innate immunity by controlling the activation of complement pathways. Dysregulation of CFI activity is associated with various immune disorders, including autoimmune diseases and increased susceptibility to infections. Understanding the molecular mechanisms underlying CFI function is essential for developing therapeutic interventions aimed at modulating the complement system. The recombination of CFI protein allows for detailed structural and functional studies, facilitating insights into its enzymatic activity and interactions with other complement components. Moreover, recombinant CFI is valuable for experimental applications, including in vitro assays and potential therapeutic uses in complement-related diseases. Research in this area aims to enhance our understanding of CFI’s role in immune regulation and its potential as a target for novel treatments, particularly in conditions where complement dysregulation contributes to pathology. The ongoing investigations into the recombinant expression, purification, and characterization of CFI are critical for advancing our knowledge of complement biology and improving clinical outcomes for patients with complement-mediated diseases.
